Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
24280-93-1
Molecular formula
C17H19O6-
Molecular weight
319.3 g/mol
Drug class
Immunosuppressant antimetabolitemycophenolic acid active moiety
Mechanism of action
Inhibits inosine monophosphate dehydrogenase (IMPDH), preferentially suppressing de-novo guanosine nucleotide synthesis in activated T and B lymphocytes and reducing lymphocyte proliferation. Specific prodrug salts/forms such as mycophenolate mofetil and mycophenolate sodium are separate dosage forms that deliver mycophenolic acid.
Indications / reported uses
Used in combination immunosuppressive regimens to prevent allograft rejection after kidney, heart or liver transplantation, depending on the particular mycophenolic acid formulation and jurisdiction
Off-label use in selected autoimmune disorders is not a universal product-authorised indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Mycophenolate Environmental Risk Assessment (ERA) (the Mycophenolate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.